| Trial | Title | Study Record Detail | Phase | Sponsor/ Collaborator |
|---|---|---|---|---|
| Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast Cancer | NCT02574455 | I | Immunomedics, Inc. | |
| Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer | NCT02161679 | II | Immunomedics, Inc. | |
| Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers | NCT01631552 | I & II | Immunomedics, Inc. |
- Click here for more information about sacituzumab govitecan.
Last Editorial Review: November 12, 2016
